Science & Technology
NanoSmart Pharmaceuticals (Licensed - LOI)
slide1.jpeg
slide2.jpeg
Sybleu, Inc.    License

A world-wide Licensing Agreement with Sybleu Inc. for its Cancer therapy by intratumoral injection of a chemotherapeutic agent in combination with a bioactive immunostimulatory agent.  The chemotherapeutic agent of claim is AQ4 & AQ4N.  The bioactive agent is derived from the group of TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand.

The concept of this invention is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.